Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PBTZ169 in Healthy Volunteers
NCT03036163Phase 1Completed
- Sponsor
- Nearmedic Plus
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of macozinone in Tuberculosis (TB) (7 cohorts), sponsored by Nearmedic Plus. Primary endpoint: Incidence of Drug-related Adverse Events at 14 days. Started Jan 2016; status: completed.
02
Drugs
macozinone
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03036163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036163.